Discovery of AvaS Enzyme Sheds Light on Bacterial Protein Production and Resistance
Antimicrobial resistance poses a significant challenge to global health, as bacteria rapidly develop resistance to existing treatments, complicating the management of infections. A recent study led by the Singapore-MIT Alliance for Research and Technology (SMART) has unveiled the discovery of aminovaleramididine synthetase (AvaS), the first identified pyridoxal phosphate (PLP)-dependent enzyme responsible for a chemical modification that influences how bacteria manage metabolic stress. This finding provides new insights into bacterial adaptation and may inform future antimicrobial therapies.
The research team, which included experts from MIT and various international institutions, found that AvaS is critical in producing a tRNA modification known as aminovaleramide cytidine (ava2C) in the bacterium Pseudomonas aeruginosa, notorious for causing severe infections like pneumonia and sepsis. Although ava2C had been previously detected in other organisms, the enzyme responsible for its synthesis was unknown until now.
Using advanced RNA modification profiling techniques, the researchers identified AvaS by screening thousands of P. aeruginosa mutants. This discovery marks a significant advancement in understanding RNA biology, particularly regarding how bacteria regulate protein production in response to environmental stresses such as antibiotic exposure.
Professor Peter Dedon, co-lead principal investigator at SMART AMR, emphasized the importance of this discovery, stating that it opens a new chapter in RNA biology and enhances our understanding of antimicrobial resistance mechanisms. The study highlights that bacteria can employ various strategies to resist antibiotics, including modifying the proteins they produce and how they respond to stress.
The research, published in Nature Chemical Biology, demonstrates that AvaS utilizes PLP, a derivative of vitamin B6, to convert lysidine into ava2C. This finding establishes PLP-dependent enzymes as a new class of tRNA-modifying enzymes, expanding the known mechanisms that bacteria use to regulate protein production.
Moreover, the presence of ava2C alters how bacteria interpret genetic information, allowing for faster and more efficient protein synthesis, which is crucial for their survival under stress conditions. This discovery not only enhances our understanding of bacterial biology but also paves the way for developing new strategies to combat drug-resistant bacteria.
The SMART AMR team plans to further investigate the implications of ava2C on bacterial stress responses and metabolism, aiming to find ways to disrupt this modification. This research could lead to novel approaches in the fight against antimicrobial resistance, which is becoming increasingly urgent as bacteria continue to evolve and evade existing treatments. The study also opens avenues for exploring similar modifications in plants and other organisms, potentially broadening the impact of this research across different fields of biology.




